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Abstract Metzincins and functionally related genes play
important roles in extracellular matrix remodeling both in
healthy and fibrotic conditions. We recently presented a
transcriptomic classifier consisting of 19 metzincins and
related genes (MARGS) discriminating biopsies from renal
transplant patients with or without interstitial fibrosis/
tubular atrophy (IF/TA) by virtue of gene expression
measurement (Roedder et al., Am J Transplant 9:517–526,
2009). Here we demonstrate that the same algorithm has
diagnostic value in non-transplant solid organ fibrosis. We
used publically available microarray datasets of 325 human
heart, liver, lung, kidney cortex, and pancreas microarray
samples (265 with fibrosis, 60 healthy controls). Expression
of nine commonly differentially expressed genes was
confirmed by TaqMan low-density arrays (Applied Bio-
systems, USA) in 50 independent archival tissue specimens
with matched histological diagnoses to microarray patients.
In separate and in combined, integrated microarray data
analyses of five datasets with 325 samples, the previously
published MARGS classifier for renal post-transplant IF/TA
had a mean AUC of 87% and 82%, respectively. These data
demonstrate that the MARGS gene panel classifier not only
discriminates IF/TA from normal renal transplant tissue, but
also classifies solid organ fibrotic conditions of human
pancreas, liver, heart, kidney, and lung tissue samples with
high specificity and accuracy, suggesting that the MARGS
classifier is a cross-platform, cross-organ classifier of
fibrotic conditions of different etiologies when compared
to normal tissue.
Keywords Fibrosis . Microarray . Classifier . Metzincins
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Introduction
Fibrosis is a tissue-repair response to chronic and severe
tissue injury, including chronic exposure to pathogens or
toxins like cigarette smoke, asbestos, and alcohol. A major
cause of long-term organ failure, fibrosis is currently
irreversible and is hence subject to extensive research
efforts. Tissue repair is a delicately balanced process of
sequential interplay of secretion of growth factors, chemo-
kines, the deposition and degradation of extracellular
matrix (ECM), angiogenesis, apoptosis, and eventually
either resolution of the injury through regeneration, or
healing accompanied by scar formation. Disruption or
deregulation of any of those processes, or persistent tissue
injury, leads to abnormal tissue repair, termed fibrosis,
which consequently results in sclerosis. The role of
inflammation as a trigger of normal and abnormal tissue
repair cascades is still under debate [2, 3].
A common denominator of fibrotic wound repair is
excessive deposition, reorganization, and remodeling of
extracellular matrix (ECM). ECM remodeling is mediated
by a number of genes and pathways, among others by the
superfamily metzincins, which are zinc-dependent metal-
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loproteases. Metzincins can be subdivided into groups of
proteins with a disintegrin and metalloprotease domain
(ADAM), ADAM with thrombospondin motif (ADAMTS),
serralysins, papalysins, and matrix metalloproteases
(MMP). All have been shown to play roles during
fibrogenesis [4, 5]. As we have previously reported, we
have extended the group of metzincins and generated a
gene set termed MARGS (metzincins and related genes).
We included transcription factors, activators, inhibitors and
substrates, and cell-surface and cytoplasmic proteins which
regulate the functions of metzincins [1]. The list of 191
MARGS includes genes with roles in epithelial cell damage
(e.g., fibrin, fibronectin, collagens), fibroblast proliferation
(e.g., TGF, TNF, SERPINE), basement membrane remod-
eling (e.g., MMP2, MMP9), fibroblast foci formation (e.g.,
TIMP1, TIMP2), as well as angiogenesis (e.g., VEGF) and
impaired re-epithelialization (e.g., MMPs/TIMPs) (Supple-
mentary Table TS1). Thus, MARGS are representative of
important phases of normal and fibrotic tissue repair.
Timely diagnosis of fibrosis through molecular markers
and classical clinical parameters may be an invaluable
indication for treatment adjustment prior to the develop-
ment of irreversible sclerosis.
We have previously demonstrated that gene expression
of MARGS correlates at large with progression of human
interstitial fibrosis/tubular atrophy (IF/TA) in renal allograft
biopsies [1]. We also showed in three independent micro-
array datasets that a gene panel consisting of 19 MARGS
could be used to classify human renal biopsies with and
without IF/TA.
Here we extend those findings and test the performance
of the IF/TA gene expression classifier in human fibrosis
of various etiologies in five different organs. Using
publically available microarray datasets, we demonstrate
first that MARGS indeed are differentially expressed
under conditions of fibrosis in aging kidney, heart failure,
liver cirrhosis, idiopathic pulmonary fibrosis, and pancre-
atitis. We confirm these data by TaqMan quantitative RT–
PCR in independent etiology-matched patient samples,
and finally show in support of our hypothesis good
diagnostic value of the MARGS-panel classifier in the
microarray datasets.
Materials and methods
Datasets
An overview of the microarray datasets is shown in Table 1.
The expression data for the kidney dataset was downloaded
from http://genome-www5.stanford.edu [6]. Gene expression
datasets for heart and lung were downloaded from Gene
Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo,
Heart: GSE5406 [7], Lung: GSE10667 [1]. Liver and
pancreas data were provided by the authors [9, 10].
Microarray analysis
Gene expression analysis was performed in Partek Genomics
Suite 6.5 (http://www.Partek.com) and R (http://www.
bioconductor.org). Where non-processed data were avail-
able, datasets were quantile normalized with RMA
background correction and median polish. The manuscript
is based on the assumption that genes are appropriately
matched to common identifiers across platforms to
achieve comparability of data. We used Entrez Gene
IDs for this purpose, as they appear to be relatively
stable over time (J.S. Marron, personal observation).
Expression signal intensities for features mapping to the
same Entrez GeneID were averaged. Pseudogenes and all
features on the platforms without Entrez Gene ID were
excluded.
Expression filters were applied to all datasets, except
those with ratio measures. Only genes with signal intensity
measurements of at least 6.5 in log2 scale in a number of
samples corresponding to 75% in the smallest analysis
group were considered further. Differentially expressed
genes were identified by ANOVA after application of a
gene list filter. No expression filter was applied for testing
the MARGS classifier. Receiver operator characteristic
(ROC) curves and calculation of the AUC was done with
the R package ROCR [11].
Classifier algorithm was linear discriminant analysis
(LDA) with leave-one-out cross-validation.
Patients for confirmation analyses
For confirmation of microarray results, we utilized
archival formalin fixed paraffin embedded (FFPE) pan-
creas, lung, liver, kidney, and heart tissue from the
Institute of Pathology, University of Berne, Switzerland.
Fibrotic and non-fibrotic tissue specimens from a total of
50 patients were utilized (Table 2). Great care was taken
to select the cases with best match to the histological
diagnosis of cases used for microarray data analyses [6–
10]. All patients remained anonymized except for age and
gender, and all studies were approved by the local ethics
commission.
Preparation of tissue
Sections 8–10 μm thick were cut from each FFPE tissue
block of healthy and fibrotic kidneys, hearts, livers, lungs,
and pancreas (n=5 per case). Sections were deparaffinized
in xylene three times for 5 min with gentle inversion. A
maximum of 150 mm2 of tissue was scraped off using a
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sterile scalpel and stencil and transferred into a 1.5-mL
microcentrifuge tube. For tissue digestion, 150 μL
Proteinase K mix (20 μg/μL; Arcturus Bucher Biotec,
Basel, Switzerland) were added, and tissue was incubated
in a thermoshaker at 37°C and 300 rpm for 20 h. All
procedures were carried out under RNase-free conditions.
Isolation of total RNA and TaqMan® custom array
microfluidic cards
Total RNA was isolated in a final volume of 12 μL using
the Paradise Plus WT RT Reagent System (Arcturus,
Bucher Biotec) according to the manufacturer’s protocol.
Total RNA was quantified using NanoDrop (Thermo
Scientific NanoDrop, USA), and quality was controlled
applying the BioAgilent, USA Nanochip (Agilent, USA).
Finally, 200 ng total RNA was reverse transcribed into
cDNA, and 50 μL Universal PCR master mix and nuclease-
free water were added up to a final volume of 100 μL. This
sample was subsequently loaded onto TaqMan custom arrays
consisting of 384-well microfluidic cards and run on ABI
PRISM 7900HT (total of 40 cycles) (Applied Biosystems).
Gene expression assays came pre-pipetted and lyophilized in
the wells. Selection of gene expression assays for the LDA
based on short amplicon size (<100 bp) and proximity to the 3′
prime end. The following assays were used: THBS2
Hs01568063_m, HYOU1 Hs00197328_m, MMP7
Hs01042795_m, MMP2 Hs00234422_m, PXN
Hs00236064_m, COL1A2 Hs01028970_m, TIMP1
Hs00171558_m, COL3A1 Hs00943809_m, and HNRNPU
Hs00244919_m. qRT–PCR results were analyzed by SDS
V2.01 (Applied Biosystems) and Partek Genomics Suite.
Triplicate TaqMan qRT–PCR Ct values were normalized by
geometric averaging of multiple internal control genes [12].
Table 1 Documentation of gene expression microarray datasets used analysis (all datasets are publically available)
Data Array type Samples
Organ Reference Source Name #
Features
#
Fibrosis
#
Control
Fibrosis Control
Kidney Rodwell GEJ et al., PLoS
Biology 2004;2:e427
http://genomewww5.
stanford.edu/
Affymetrix HG-U133A
and B
44,928 11 16 IF/TA 3 IF/TA 0–1
Heart Hannenhalli S et al.,
Circulation, 2006;114:
1269–1276
GEO
GSE5406
Affymetrix HG-U133A 22,283 194 16 Systolic heart
failure
Non-failing
Liver Utsunomiya T et al., World
J Gastroenterol,
2007;13:383–390
Authors Agilent Human 1A 22,153 15 8 MFI adj>10 MFI adj=0
Lung Konishi K et al., Am J
Respir Crit Care Med,
2009;180:167–175
GEO
GSE10667
Agilent 4×4 4k
Whole Human
Genome
43,376 31 15 IPF; IPF+Aex Normal
Pancreas Binkley CE et al., Pancreas
2004;29:254–263
Authors Affymetrix HuGeneFL 7,129 15 5 Adenocarc.,
pancreatitis
Normal
Table 2 Information on samples used for TaqMan qRT–PCR confirmation analysis (samples were selected to match the setting of the samples
used for the microarray studies as close as possible)
Organ Group Tissue specification Diagnosis # Age (years) % Male
Kidney Control Tumor unaffected kidney
cortex of nephrectomy
Wilms tumor 5 5 +7/−3 60
Fibrosis Renal carcinoma 5 77 +7/−6 80
Heart Control Time point zero biopsy Healthy 5 46 +17/−26 80
Fibrosis Explant Terminal cardiac failure 5 56 +9/−7 100
Liver Control Tumor unaffected region
of hepatectomy
Cancer metastasis 5 60 +16/−21 80
Fibrosis Hepatectomy Liver cirrhosis 5 53 +8/−6 60
Lung Control Tumor unaffected region
of resectomy
Primary lung cancer; cancer
metastasis
3 62 +16/−13 40
Fibrosis Resectomy Usual interstitial pneumonia 5 74 +12/−11 60
Pancreas Control Tumor unaffected region
of pancreatectomy
Pancreatic carcinoma:
pseudomyxoma peritonei
4 58 +12/−14 60
Fibrosis Pancreatectomy Chronic pancreatitis 5 57 +24/−17 60
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Results
Data pre-processing
We have previously shown that MARGS are differentially
expressed in conditions of renal transplant interstitial
fibrosis and tubular atrophy (IF/TA) [1]. In addition, a
panel of 19 MARGS genes in conjunction with the decision
algorithm Linear Discriminant Analysis had been identified
as molecular marker of IF/TA in renal allografts. To
investigate the relevance of MARGS in fibrotic, non-
transplant conditions of various etiologies, we turned to
publically available microarray datasets and compared
cases of healthy controls and fibrosis (Table 1). In the
kidney cortex dataset [6], we grouped samples with IF/TA
grade 0–1, so that mild fibrosis was included in the control
group. Those were compared to samples with severe IF/TA
(grade 3). For the heart analysis, we used microarray data
from 194 samples from advanced systolic heart failure and
from 16 non-failing hearts [7]. Heart failure patients
suffered either from ischemic (n=86) or idiopathic dilated
(n=108) cardiomyopathy. This difference was neglected in
the present analysis. The lung analysis comprised samples
from 23 patients with interstitial pulmonary fibrosis (IPF)
and eight with acute exacerbation of IPF (IPF-AEx) [8]. For
the purpose of our study, these two groups were combined
to one and compared to 16 samples from patients with
normal lung histology. Samples for the liver analysis were
selected from the healthy control group and from those
patients with an adjusted morphologic fibrosis index (MFI)
score ≥10 (average F-score for this group is 3.4). The
adjusted MFI is the mean MFI determined from nine
section images, adjusted by a factor of 1.13, which corrects
for a mean MFI of 1.13 in samples of healthy control
patients [9]. The majority of the fibrosis samples originated
from patients with hepatocellular carcinoma, most of which
were positive for hepatitis C virus (HCV) antibody. Finally,
the pancreas dataset consisted of samples from patients with
chronic pancreatitis (n=5), pancreatic adenocarcinoma (n=
10), and five normal pancreas samples [10]. Chronic
pancreatitis and adenocarcinoma samples were grouped
into one.
Due to the different platforms and population of features
on the arrays, different numbers of MARGS are represented
on the platforms. For instance, the kidney cortex dataset
with HG-U133A and B included 175 MARGS, while 100
MARGS were represented on the platform of the pancreas
dataset. This has implications for the comparison of
differentially expressed MARGS, as we do not have
information on the expression of many MARGS on some
of the platforms (see below).
The initial analytical steps had to be adjusted to each
dataset. The kidney cortex data where distributed on HG-
U133A and HG-U133B arrays. We used only array pairs
which had been generated from the same patient RNA. As
99 probesets are shared between both array types, data were
merged into one matrix by mean adjustment of the
expression values of those probesets. The signal intensities
of the pancreas dataset were floored to a minimum value of
10 and log2 transformed. The liver dataset had been Lowess
normalized. As the samples had been split into training and
test set by the authors, we treated the technical effect by
mean adjustment. Sample A47, adjusted morphologic
fibrosis index (MFI) 17.43, was excluded in the further
analysis due outlier-like behavior which could not be
explained with the data at hand.
Differentially expressed MARGS
Figure 1 shows principal component analysis (PCA) of
differentially expressed MARGS which pass the expres-
sion filter (see “Materials and methods”) and had a false
discovery rate q-value qFDR <0.01 in each dataset
separately. The number of MARGS with differential
expression naturally is dependent on the significance of
biological/clinical differences between the sample groups,
but also influenced by the platform design, i.e., how many
MARGS are represented on the platforms. In kidney
cortex, 59 of overall 175 MARGS on the platform pass
our filter criteria and only four of a total of 179 MARGS
in liver.
It is obvious that differentially expressed MARGS are
sufficient in the kidney cortex, liver, and pancreas dataset to
separate fibrosis samples from control samples. The PCA of
the heart samples showed some overlap between normal
and fibrotic samples due to the inclusion of samples with
mild to very mild grades of fibrosis. In lung, there are three
samples of the control group, GSM269754, GSM269762,
and GSM269757, which display extreme behavior with
respect to MARGS expression and tend to be placed close
to the fibrosis group. Technical or biological/clinical
reasons not known to us may account for this.
Five-way Venn diagram
Uniformly deregulated genes in kidney cortex, heart, liver,
lung, and pancreas fibrosis were identified by Venn
analyses, comparing all deregulated MARGS in each organ
fibrosis dataset having a qFDR <0.1 (Fibrosis vs. Control)
after expression filter. In this analysis, we chose a larger
qFDR threshold to compensate for the—in relation to the
other datasets—larger qFDR values in the liver dataset. We
had also noticed that the set of MARGS with smallest
qFDR in liver are different from the set of MARGS with
smallest qFDR in the other datasets. To recruit a sufficient
number of MARGS as candidates for qRT–PCR confirma-
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tion from this analysis, we applied a more permissive qFDR
cutoff.
Eighty-five MARGS in kidney cortex were compared to
40 MARGS in heart fibrosis, 48 MARGS in liver fibrosis,
110 MARGS in lung fibrosis, and 78 MARGS in pancreas
fibrosis (Fig. 2a). The set union formed by all five datasets
consisted of tissue inhibitor of metalloproteinase 1 (TIMP1)
and hypoxia upregulated protein 1 (HYOU1). The analyses
revealed that 14 MARGS were only deregulated in kidney
fibrosis, whereas 25 genes were identified to be solely
deregulated in lung fibrosis, two genes in heart fibrosis,
seven genes in liver fibrosis, and 11 in pancreas fibrosis
(Fig. 2b). Nine genes were differentially expressed in
kidney cortex, liver, lung, heart, and pancreas, but not in
liver. These genes were collagen, type I, alpha 1
(COL1A1), collagen type I, alpha 2 (COL1A2), collagen
type III, alpha 1 (COL3A1), matrix metallopeptidase 2
(MMP2), secreted protein, acidic, cysteine-rich (SPARC),
thrombospondin 2 (THBS2), thrombospondin 3 (THBS3),
TIMP metallopeptidase inhibitor 3 (TIMP3), and vascular
endothelial growth factor C (VEGFC). Genes belonging to
the family of thrombospondins (THBS) were deregulated in
each organ. THBS2, previously identified as IF/TA marker
in kidney allograft biopsies (1), was deregulated in fibrosis
of all organs but liver. Here, the family member THBS1
was deregulated. MMP7, besides THBS2, another candi-
date as IF/TA marker, showed deregulation in kidney,
pancreas, and lung fibrosis but not in liver and heart
(Fig. 2b).
Cross-organ deregulated MARGS are confirmed
in independent patient samples
From the list of 11 MARGS which were differentially
expressed in all organs or all organs but liver, and from
results of our previous studies [1], we selected seven
MARGS for confirmation analyses: THBS2, TIMP1,
COL1A2, COL3A1, HYOU1, MMP2, and MMP7. As
control genes served two genes which had a coefficient of
variation less than 7.5 % in each dataset, heterogeneous
nuclear ribonucleoprotein U (HNRNPU) and paxillin
(PXN). Archival biopsy specimens of patients with
Fig. 1 Principal component analysis (PCA) of samples with or
without fibrosis from published datasets. Differentially expressed
MARGS are sufficient to separate fibrotic samples from healthy [or
mild fibrosis (kidney)] in kidney, heart, liver, lung, and pancreas. Each
sphere represents one sample. For visualization purposes, ellipsoids
which encompass 95% of the samples per group were added. Criterion
for differential expression is a qFDR <0.01 after expression filter (see
“Materials and methods”). Number before bracket is the number of
MARGS genes with qFDR <0.01, the number inside the bracket is the
number of MARGS represented on the array platform
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matched histological diagnosis to microarrays served as
RNA source (Table 2, “Materials and methods”).
Of 28 confirmation tests in kidney cortex, heart, lung, and
pancreas, 25 (89%) confirmed the direction of expression
changes observed in the microarray datasets (Fig. 3a). Of the
three which could not be confirmed, MMP7 was expressed
at low levels in the heart microarray dataset and had not
passed the qFDR filter. The other two tests which failed were
COL3A1 in kidney cortex and TIMP1 in pancreas.
THBS2 and MMP2 were upregulated in fibrosis of all
organs. HYOU1 showed increased expression in fibrosis of
kidney, liver, and lung, and showed decreased expression in
heart and pancreas fibrosis. TIMP1 was upregulated in all
organs except heart (Fig. 3a). The same pattern was
observed for MMP7 with decreased expression only in
heart fibrosis. Highest expression values in heart fibrosis
were observed for COL3A1 and COL1A2 (fc vs. Normal
0.73 and 0.61, log2 scale, respectively). All candidate
MARGS showed increased expression in pancreas, liver,
and lung fibrosis; only in heart and kidney fibrosis
decreased expression was identified for certain selected
MARGS when compared to healthy tissue (Fig. 3a). As
shown in Fig. 3b, TaqMan qRT–PCR data lead to cluster
formation of in-house samples according to diagnosis in a
PCA in all five tissues.
Interestingly, out of seven liver tests, only two could be
confirmed, MMP7 and MMP2, where MMP2 had a small
fold change in the microarray dataset (0.03, log2 scale). All
candidate MARGS were upregulated in liver fibrosis in the
in-house samples, while five of seven were downregulated
in the microarray dataset.
Classifier analysis
We have previously shown in an in-house gene expression
microarray dataset as well as other published datasets that a
classifier model consisting of 19 MARGS in combination
with Linear Discriminant Analysis decision algorithm can
discriminate human renal allograft biopsies with interstitial
fibrosis and tubular atrophy (IF/TA) from those without [1].
To test our hypothesis, that the same classifier panel could
discriminate fibrosis of different etiology from non-fibrosis
in non-transplant setting, we applied the published classifier
to the microarray datasets, including internal leave-one-out
cross-validation.
Without expression filter, the MARGS classifier list was
applied to the datasets, along with the algorithm Linear
Discriminant Analysis and full leave-one-out internal cross-
validation. As not all MARGS of the classifier panel were
represented on each platform, gene subsets of the classifier
had to be used in some instances (Table 3). In kidney
cortex, 18 of the 19 classifier MARGS could be used, in
heart 15, in lung and liver all 19, and in pancreas 10
(Supplementary Table TS2). As can be seen in Table 3, the
performance estimate “area under the ROC curve” (AUC)
for the binary prediction of “fibrotic” or “healthy” exceeded
0.78 in each dataset. The mean AUC was 0.872. The mean
accuracy was 88%. The best classification rate was
achieved in kidney cortex, where all samples were correctly
classified; the lowest performance was measured with the
liver dataset where the correct classification rate was 72.7%
(AUC=0.786). The significance of the AUC was estimated
by bootstrapping (seed=100,000). A lower limit of the 95th
Fig. 2 Differentially expressed MARGS in fibrosis datasets. a Five-
way Venn diagram identifies two MARGS genes which are differen-
tially expressed in all five datasets. Nine additional MARGS are
differentially expressed in all datasets but liver (shaded fields).
Criterion for differential expression is a qFDR <0.1 and passing an
expression filter (see “Materials and methods”). b Gene lists from
Venn diagram. Genes which were selected for confirmation analyses
are underlined. In addition, MMP7 was selected based on previous
findings (see main text). MMP7 was differentially expressed in
kidney, lung, and pancreas microarray datasets (not shown)
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Fig. 3 TaqMan RT–PCR confirmation of microarray data in
independent sample sets. a TaqMan qRT–PCR confirmation of seven
MARGS genes in five tissues. In kidney, heart, lung, and pancreas,
89% of the tests successfully confirmed the direction of expression
changes. In liver, only two of seven tests were successful. TaqMan
qRT–PCR: *p<0.1, **p<0.05; microarray: *qFDR value<0.1, qFDR
value<0.05. b Principal component analysis of normalized TaqMan
qRT–PCR values of seven MARGS. In an unsupervised analysis, the
expression values of the genes separate the tissue samples in each
comparison by diagnosis. Each sphere represents one sample. For
visualization purposes, ellipsoids which encompass 95% of the
samples per group were added
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percentile confidence interval larger than 0.5 indicates that
the model performance is significantly better than random.
This is the case in all analyses. A chi-square p value <0.5
indicates a significant dependence of the actual and the
predicted values. In all tests, the chi-square p value is
smaller than 0.5.
Next we integrated all five datasets across tissue and
platform to obtain a set with 265 fibrosis samples and 65
control samples (Table 3). Due to the integration of the
pancreas dataset, only 10 MARGS genes could be used in
this approach: CD44, THBS2, VEGFA, PLG, TNFAIP3,
LAMB1, TNFSF10, COL3A1, THBS1, and MGP. Despite
these limitations, the classifier performance reached a
significant AUC of 0.82 and an accuracy of 88%.
Discussion
Genes comprising the MARGS gene set are known to be
involved in remodeling of ECM under healthy and disease
conditions [13–16]. It is therefore conceivable that they
play important roles in fibrotic/sclerotic conditions in
organs, which may result in response to tissue injury, or
as progression of age. Along those lines, differential
expression of hypoxia-regulated genes, such as HYOU1
(hypoxia up-regulated 1), HIF1-target gene TIMP1 in all
datasets, and THBS2, MMPs and collagens I and III in all
but the liver microarray dataset are in correspondence with
earlier findings which showed an involvement of hypoxia
in fibrosis (kidney [17, 18], pancreas [19], lung [20, 21],
heart [22–24], liver [25–27]).
We were able to validate the gene expression trends we
saw in kidney, heart, lung, and pancreas in 89% (25 of 28
tests) of the TaqMan qRT–PCR tests using archival tissue
specimens, which is an exceptionally high rate considering
that all sample sets were completely independent. Confir-
mation results were unsatisfactory for the liver microarray
data (Fig. 3a), where five of seven tests failed to validate
the microarray data, although the TaqMan data themselves
were significantly different between healthy and fibrotic
samples (Fig. 3a, b). Compared to the datasets of the other
organs, only few MARGS in the liver dataset had qFDR
values <0.01 (Fig. 1). In our own analysis of the liver
microarray data, we observed similar trends of gene
expression changes as the Utsunomiya group and confirm
the importance of inflammatory genes in that dataset (not
shown). We found that most MARGS were in fact
underrepresented in the fibrosis group (not shown), while
proinflammatory genes were largely overrepresented and
correlated with the adjusted MFI fibrosis grade, as
published [9]. Recently, the group of Takahara has shown
in gene expression studies of fibrosis in HCV patients that
ECM modulatory genes in general positively correlate withTa
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the METAVIR F-score 1 through 4, and some genes had
peak expression changes in fibrosis score 2 and 3 [28]. In
accordance with these data, we observe similar trends in
expression changes with MARGS ECM genes when we use
the categorical average METAVIR F-score instead of the
continuous adjusted MFI; however, the qFDR values for
the individual genes increase (not shown). We do not obtain
a better correlation of TaqMan qRT–PCR and microarray
data in terms of trends of “over- and under-representation”
when we use the METAVIR F-score annotation of the
microarray data. We believe that the differences between
the microarray data of Utsunomiya’s group and the
Inselspital TaqMan qRT–PCR data may reveal differences
in etiology or be of other clinical or biological origin which
was impossible to capture from the annotations at hand
despite our efforts to match our patient groups as much as
possible with the published samples. The increases in, e.g.,
MMP2 and collagens type I and III that we observe in
TaqMan qRT–PCR data match well with published findings
(see [29] for review). Separately, the two analyses revealed
significant differences for MARGS between liver fibrosis
and healthy groups, leading to a separation of the sample
groups in PCA of the microarray data and of the TaqMan
qRT–PCR data (Figs. 1 and 3, respectively).
Let us consider two major valid methods of identifying
molecular markers, e.g., gene expression panels in combi-
nation with a decision algorithm. One method, let us use the
term “gene-to-biology-method”, essentially employs testing
of all features on a technology platform (such as micro-
arrays) and then, once the feature panel has been identified,
links to the biology and pathways underlying the studied
disease. While in theory it is not given that genes, or
generally speaking, features, of a classifier which has been
identified in an unbiased way are involved in the disease
biology, in practice many researchers and clinicians feel
much more comfortable with the classifier panel if they do,
as it is intuitively plausible [30]. In our studies, we have
employed another method, a “biology-to-gene-method”.
We first considered the biology of the diseases or
complications we were interested in, used literature
searches and knowledge to assemble a list of genes which
play important roles in that biology, and asked whether
those genes could serve as the starting gene list to generate
a classifier panel. Hence, we easily linked the biology of
fibrosis, post-transplant or in other etiologies, with molec-
ular markers (the MARGS).
We previously showed that a subset of MARGS can be
used to discriminate human renal allograft biopsy samples
with IF/TA from non-IF/TA samples [1]. In the present
study, we demonstrate that the IF/TA MARGS transcrip-
tomics classifier panel also classifies solid organ fibrotic
conditions of human aging kidney, cardiac failure, hepatic
cirrhosis, pulmonary fibrosis, and pancreatitis tissue sam-
ples with high accuracy, AUC, specificity, and sensitivity
(the sensitivity for the liver dataset was exceptionally low
and the reason remains uncertain). Our studies suggest that
the MARGS classifier is a valid candidate for a cross-
platform, cross-organ classifier of normal tissue vs. fibrotic
conditions of different etiologies. Obvious next steps are
the application of the classifier to blood sample gene
expression data, to see whether a minimally invasive, easily
applicable gene expression marker could accompany or
outperform other minimally and non-invasive methods [31–
34]. Given that, e.g., plasma levels of TIMP1 protein have
been found elevated in diastolic dysfunction [35], transfer
of our data to, for instance, peripheral blood appears
promising. From a clinical perspective, the MARGS
classifier may be used to detect fibrosis prior to the
development of irreversible tissue sclerosis, and thus
enhance organ preservation through treatment adjustment.
The classifier should be tested for its ability to diagnose
fibrosis at a very early time point, ideally before fibrosis is
visible on tissue sections and therapy is still most effective.
In this respect, it will be interesting to test the classifier for
its ability to be utilized to monitor drug effects. Future work
will tell if some of the genes present in the MARGS panel
represent therapeutic targets.
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